Proteomics for the discovery of nuclear bile acid receptor FXR targets

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 8, 2011, Pages 836-841

  Gardmo, Cissi ^a   Tamburro, Antonio ^a   Modica, Salvatore ^a   Moschetta, Antonio ^a,b  

^a Consorzio Mario Negri Sud ^*  (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Expression profiling; FXR; Mitochondrial; Nuclear receptor; Post transcriptional modification; Proteomic analysis

Indexed keywords

BILE ACID; FARNESOID X RECEPTOR; OBETICHOLIC ACID;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FUNCTIONAL PROTEOMICS; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN MICROARRAY; REAL TIME POLYMERASE CHAIN REACTION; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; WESTERN BLOTTING;

ANIMALS; BILE ACIDS AND SALTS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROTEOMICS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

MUS;

EID: 79958260884     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.03.009     Document Type: Article

References (34)

1. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P., Evans R.M. The nuclear receptor superfamily: the second decade. Cell 1995, 83:835-839.
2. Chawla A., Repa J.J., Evans R.M., Mangelsdorf D.J. Nuclear receptors and lipid physiology: opening the X-files. Science 2001, 294:1866-1870.
3. Yang X., Downes M., Yu R.T., Bookout A.L., He W., Straume M., Mangelsdorf D.J., Evans R.M. Nuclear receptor expression links the circadian clock to metabolism. Cell 2006, 126:801-810.
4. Bookout A.L., Jeong Y., Downes M., Yu R.T., Evans R.M., Mangelsdorf D.J. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 2006, 126:789-799.
5. G. Di Leva, P. Gasparini, C. Piovan, A. Ngankeu, M. Garofalo, C. Taccioli, M.V. Iorio, M. Li, S. Volinia, H. Alder, T. Nakamura, G. Nuovo, Y. Liu, K.P. Nephew, C.M. Croce, MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer, J Natl Cancer Inst 102 706-721.
6. Yamagata K., Fujiyama S., Ito S., Ueda T., Murata T., Naitou M., Takeyama K., Minami Y., O'Malley B.W., Kato S. Maturation of microRNA is hormonally regulated by a nuclear receptor. Mol. Cell 2009, 36:340-347.
7. Rainer J., Ploner C., Jesacher S., Ploner A., Eduardoff M., Mansha M., Wasim M., Panzer-Grumayer R., Trajanoski Z., Niederegger H., Kofler R. Glucocorticoid-regulated microRNAs and mirtrons in acute lymphoblastic leukemia. Leukemia 2009, 23:746-752.
8. J. Lee, A. Padhye, A. Sharma, G. Song, J. Miao, Y.Y. Mo, L. Wang, J.K. Kemper, A pathway involving farnesoid X receptor and small heterodimer partner positively regulates hepatic sirtuin 1 levels via microRNA-34a inhibition, J Biol Chem 285 12604-12611.
9. Song G., Wang L. Transcriptional mechanism for the paired miR-433 and miR-127 genes by nuclear receptors SHP and ERRgamma. Nucleic Acids Res. 2008, 36:5727-5735.
10. Wang X., Gocek E., Liu C.G., Studzinski G.P. MicroRNAs181 regulate the expression of p27Kip1 in human myeloid leukemia cells induced to differentiate by 1,25-dihydroxyvitamin D3. Cell Cycle 2009, 8:736-741.
11. Parks D.J., Blanchard S.G., Bledsoe R.K., Chandra G., Consler T.G., Kliewer S.A., Stimmel J.B., Willson T.M., Zavacki A.M., Moore D.D., Lehmann J.M. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999, 284:1365-1368.
12. Makishima M., Okamoto A.Y., Repa J.J., Tu H., Learned R.M., Luk A., Hull M.V., Lustig K.D., Mangelsdorf D.J., Shan B. Identification of a nuclear receptor for bile acids. Science 1999, 284:1362-1365.
13. Wang H., Chen J., Hollister K., Sowers L.C., Forman B.M. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell 1999, 3:543-553.
14. Modica S., Moschetta A. Nuclear bile acid receptor FXR as pharmacological target: are we there yet?. FEBS Lett. 2006, 580:5492-5499.
15. Sinal C.J., Tohkin M., Miyata M., Ward J.M., Lambert G., Gonzalez F.J. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000, 102:731-744.
16. Kok T., Hulzebos C.V., Wolters H., Havinga R., Agellon L.B., Stellaard F., Shan B., Schwarz M., Kuipers F. Enterohepatic circulation of bile salts in farnesoid X receptor-deficient mice: efficient intestinal bile salt absorption in the absence of ileal bile acid-binding protein. J. Biol. Chem. 2003, 278:41930-41937.
17. Kim I., Ahn S.H., Inagaki T., Choi M., Ito S., Guo G.L., Kliewer S.A., Gonzalez F.J. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J. Lipid Res. 2007, 48:2664-2672.
18. Huang W., Ma K., Zhang J., Qatanani M., Cuvillier J., Liu J., Dong B., Huang X., Moore D.D. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science 2006, 312:233-236.
19. Yang F., Huang X., Yi T., Yen Y., Moore D.D., Huang W. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res. 2007, 67:863-867.
20. Kim I., Morimura K., Shah Y., Yang Q., Ward J.M., Gonzalez F.J. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis 2007, 28:940-946.
21. Modica S., Murzilli S., Salvatore L., Schmidt D.R., Moschetta A. Nuclear bile acid receptor FXR protects against intestinal tumorigenesis. Cancer Res. 2008, 68:9589-9594.
22. Inagaki T., Moschetta A., Lee Y.K., Peng L., Zhao G., Downes M., Yu R.T., Shelton J.M., Richardson J.A., Repa J.J., Mangelsdorf D.J., Kliewer S.A. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc. Natl Acad. Sci. U.S.A. 2006, 103:3920-3925.
23. Lorenzo-Zuniga V., Bartoli R., Planas R., Hofmann A.F., Vinado B., Hagey L.R., Hernandez J.M., Mane J., Alvarez M.A., Ausina V., Gassull M.A. Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. Hepatology 2003, 37:551-557.
24. A.M. Thomas, S.N. Hart, B. Kong, J. Fang, X.B. Zhong, G.L. Guo, Genome-wide tissue-specific farnesoid X receptor binding in mouse liver and intestine, Hepatology 51 1410-1419.
25. Fiorucci S., Rizzo G., Donini A., Distrutti E., Santucci L. Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol. Med. 2007, 13:298-309.
26. Pellicciari R., Fiorucci S., Camaioni E., Clerici C., Costantino G., Maloney P.R., Morelli A., Parks D.J., Willson T.M. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem. 2002, 45:3569-3572.
27. Shevchenko A. Evaluation of the efficiency of in-gel digestion of proteins by peptide isotopic labeling and MALDI mass spectrometry. Anal. Biochem. 2001, 296:279-283.
28. Pellicciari R., Sato H., Gioiello A., Costantino G., Macchiarulo A., Sadeghpour B.M., Giorgi G., Schoonjans K., Auwerx J. Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5. J. Med. Chem. 2007, 50:4265-4268.
29. Ding S.J., Li Y., Shao X.X., Zhou H., Zeng R., Tang Z.Y., Xia Q.C. Proteome analysis of hepatocellular carcinoma cell strains, MHCC97-H and MHCC97-L, with different metastasis potentials. Proteomics 2004, 4:982-994.
30. Zheng S., Ruan Y., Wu Z., Tang J. The relationship between 67KD laminin receptor expression and metastasis of hepatocellular carcinoma. J. Tongji Med. Univ. 1997, 17:200-202. 224.
31. Xu L., Hui L., Wang S., Gong J., Jin Y., Wang Y., Ji Y., Wu X., Han Z., Hu G. Expression profiling suggested a regulatory role of liver-enriched transcription factors in human hepatocellular carcinoma. Cancer Res. 2001, 61:3176-3181.
32. White D.L., Li D., Nurgalieva Z., El-Serag H.B. Genetic variants of glutathione S-transferase as possible risk factors for hepatocellular carcinoma: a HuGE systematic review and meta-analysis. Am. J. Epidemiol. 2008, 167:377-389.
33. Covolo L., Gelatti U., Talamini R., Garte S., Trevisi P., Franceschi S., Franceschini M., Barbone F., Tagger A., Ribero M.L., Parrinello G., Donadon V., Nardi G., Donato F. Alcohol dehydrogenase 3, glutathione S-transferase M1 and T1 polymorphisms, alcohol consumption and hepatocellular carcinoma. Cancer Causes Control 2005, 16:831-838.
34. Yamada S., Ohira M., Horie H., Ando K., Takayasu H., Suzuki Y., Sugano S., Hirata T., Goto T., Matsunaga T., Hiyama E., Hayashi Y., Ando H., Suita S., Kaneko M., Sasaki F., Hashizume K., Ohnuma N., Nakagawara A. Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas. Oncogene 2004, 23:5901-5911.